The latest trading day saw UnitedHealth Group (UNH) settling at $393.06, representing a -1.94% change from its previous close.
UNH is investing nearly $1.5B in AI to expand Optum Insight's software offerings, boost efficiency and unlock new growth opportunities.
UnitedHealth (UNH) stock is inching lower after the healthcare giant confirmed the sale of a partial stake in its Optum Health Florida primary-care clinic network, including WellMed operations, to private equity firm TPG. The transaction allows UNH to bring in strategic growth capital while maintaining an equity interest in the regional clinic footprint.
UnitedHealth Group (NYSE:UNH | UNH Price Prediction) stock is down 3% to $388.58 in early Wednesday trading after Bloomberg reported the company sold an interest in part of its Florida WellMed primary-care clinics.
UNH's 39% six-month rally reflects improving medical costs, stronger earnings estimates and a sharper focus on profitable businesses.
UNH is showing signs of recovery as medical costs improve, Optum gains momentum and 2026 earnings guidance rises.
Rising employer healthcare costs could boost Marsh's consulting demand and create growth avenues for UnitedHealth and Centene through cost-control solutions.
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.
UnitedHealth Group's United Healthcare health insurance business said 1,700 diagnostic codes tied to treatments and procedures will soon no longer require prior approval.
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
UnitedHealth Group's stronger six-month return, improving UnitedHealthcare and Optum results and attractive valuation make it the better buy.
UNH outpaces ELV with stronger earnings prospects, improving Medicare profitability, greater upside and a more favorable risk-reward profile.